Chronic Hepatitis News

Data from a large, real-world study contributed to the growing safety and efficacy evidence of transplanting hepatitis C-infected organs into aviremic patients in the direct-acting antiviral era.

Patients with current or prior hepatitis C infection were willing to engage in alcohol intervention including counseling and referral to treatment when encouraged by liver medical providers, according to data published in Hepatology.

Patients who failed to achieve sustained virologic response after initial treatment for hepatitis C achieved high cure rates during retreatment after switching from an NS5A inhibitor direct-acting antiviral to a protease inhibitor.

Screening all patients with solid tumors for hepatitis B before they underwent chemotherapy was the most cost-effective strategy, compared with not screening or only screening high-risk patients, according to a published study.

Patients with liver disease, especially those with advanced liver disease, may face comorbid renal-related complications including impaired renal function and hepatorenal syndrome. Liver disease and kidney care have also been tied lately between use of hepatitis C-infected kidneys in nonviremic patients.

This year’s The Liver Meeting provided many exciting updates for viral hepatitis care ranging from steps toward eliminating hepatitis C to improving hepatitis B treatment options through data on hepatitis D.

Trio Health presented results from four studies at The Liver Meeting 2019 that showed novel outcomes in patients treated for hepatitis B with Vemlidy or hepatitis C with Vosevi.

The FDA approved changes to the product labels for direct-acting antivirals Harvoni, Epclusa, and Vosevi to include new efficacy and safety data for adults with hepatitis C and severe renal impairment, including those who require dialysis.

BOSTON — The Hepatitis C Leaders in Primary Care program, or HELP-C, engaged primary care physicians to successfully screen and treat veterans with hepatitis C through comanagement with a specialist liver team, according to a study presented at The Liver Meeting 2019.

BOSTON — Triple combination therapy with lonafarnib, ritonavir, and Lambda for chronic hepatitis D appeared safe and tolerable for up to 6 months in most patients and led to high rates of RNA decline, according to data presented at The Liver Meeting 2019.